Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionchromatin binding

SBNO1 EGR2 MCM3AP RERE BRD2

6.68e-04739205GO:0003682
GeneOntologyMolecularFunctiontransmembrane receptor protein tyrosine kinase activity

DDR1 EPHA1

1.91e-0365202GO:0004714
GeneOntologyMolecularFunctiontransferase activity, transferring phosphorus-containing groups

ART3 GUCY2F DDR1 EPHA1 BRD2

1.94e-03938205GO:0016772
GeneOntologyMolecularFunctionhistone binding

SBNO1 MCM3AP BRD2

2.23e-03265203GO:0042393
GeneOntologyMolecularFunctionprotein kinase activity

GUCY2F DDR1 EPHA1 BRD2

2.66e-03600204GO:0004672
GeneOntologyMolecularFunctiontransmembrane receptor protein kinase activity

DDR1 EPHA1

3.24e-0385202GO:0019199
Domain-

DDR1 EPHA1 GLB1L2

6.23e-05732032.60.120.260
DomainGalactose-bd-like

DDR1 EPHA1 GLB1L2

1.32e-0494203IPR008979
DomainPkinase_Tyr

GUCY2F DDR1 EPHA1

3.37e-04129203PF07714
DomainSer-Thr/Tyr_kinase_cat_dom

GUCY2F DDR1 EPHA1

4.10e-04138203IPR001245
DomainWW

GAS7 SETD2

1.14e-0347202PF00397
DomainWW

GAS7 SETD2

1.19e-0348202SM00456
DomainWW_DOMAIN_2

GAS7 SETD2

1.35e-0351202PS50020
DomainWW_DOMAIN_1

GAS7 SETD2

1.35e-0351202PS01159
DomainWW_dom

GAS7 SETD2

1.40e-0352202IPR001202
Domain-

ESRRB RERE

1.68e-03572023.30.50.10
DomainZnf_NHR/GATA

ESRRB RERE

1.74e-0358202IPR013088
DomainTyrKc

DDR1 EPHA1

3.95e-0388202SM00219
DomainTyr_kinase_cat_dom

DDR1 EPHA1

3.95e-0388202IPR020635
DomainPROTEIN_KINASE_TYR

DDR1 EPHA1

4.77e-0397202PS00109
DomainTyr_kinase_AS

DDR1 EPHA1

4.77e-0397202IPR008266
DomainProt_kinase_dom

GUCY2F DDR1 EPHA1

1.46e-02489203IPR000719
Pubmed

Adam22 is a major neuronal receptor for Lgi4-mediated Schwann cell signaling.

EGR2 ADAM22

1.13e-05920220220021
Pubmed

Lgi4 promotes the proliferation and differentiation of glial lineage cells throughout the developing peripheral nervous system.

EGR2 ADAM22

5.93e-052020221068328
Pubmed

Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.

DDR1 EPHA1

1.18e-042820218593464
Pubmed

The protein network surrounding the human telomere repeat binding factors TRF1, TRF2, and POT1.

ZC3H13 MCM3AP BRD2

1.90e-0419720320811636
Pubmed

Gbx2 is essential for maintaining thalamic neuron identity and repressing habenular characters in the developing thalamus.

GAS7 ESRRB

2.42e-044020226297811
Pubmed

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.

SETD2 BRD2

2.42e-044020228805822
Pubmed

Common genetic variation and the control of HIV-1 in humans.

DDR1 NBEA

2.42e-044020220041166
Pubmed

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

DDR1 EPHA1

2.42e-044020230898150
Pubmed

Charcot-Marie-Tooth Hereditary Neuropathy Overview

EGR2 MCM3AP

3.49e-044820220301532
Pubmed

Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.

GAS7 SETD2 MCM3AP RERE BRD2

3.50e-04111620531753913
InteractionMCRS1 interactions

EGR2 GAS7 RERE BRD2

7.54e-05235204int:MCRS1
InteractionMED30 interactions

ZC3H13 ESRRB BRD2

7.57e-0584203int:MED30
InteractionMED29 interactions

ZC3H13 ESRRB BRD2

1.35e-04102203int:MED29
InteractionMED19 interactions

ZC3H13 ESRRB BRD2

1.51e-04106203int:MED19
InteractionMED26 interactions

ZC3H13 ESRRB BRD2

1.55e-04107203int:MED26
InteractionRBBP5 interactions

EGR2 ZC3H13 ESRRB RERE

1.63e-04287204int:RBBP5
Cytoband6p21.3

DDR1 BRD2

5.26e-032502026p21.3
CoexpressionGSE22886_CD8_TCELL_VS_BCELL_NAIVE_DN

SBNO1 EGR2 DDR1 IL4R

1.39e-05198204M4429
CoexpressionKAECH_NAIVE_VS_DAY8_EFF_CD8_TCELL_UP

EGR2 IL4R RERE PATJ

1.45e-05200204M3012
CoexpressionGAUTAM_EYE_IRIS_CILIARY_BODY_CRYAA_HIGH_CILIARY_BODY_CELLS

EGR2 RERE BRD2

3.24e-0582203M43626
CoexpressionHOLLERN_EMT_BREAST_TUMOR_DN

DDR1 EPHA1 PATJ

1.08e-04123203M624
CoexpressionHOLLERN_EMT_BREAST_TUMOR_DN

DDR1 EPHA1 PATJ

1.43e-04135203MM965
CoexpressionZHONG_PFC_C3_ASTROCYTE

GAS7 NBEA MCM3AP RERE

1.92e-04389204M39102
CoexpressionLAKE_ADULT_KIDNEY_C4_PROXIMAL_TUBULE_EPITHELIAL_CELLS_S2

NBEA RERE PATJ

3.12e-04176203M39223
CoexpressionGSE17301_IFNA2_VS_IFNA5_STIM_ACD3_ACD28_ACT_CD8_TCELL_UP

IL4R EPHA1 RERE

4.40e-04198203M8036
CoexpressionGSE11057_NAIVE_VS_EFF_MEMORY_CD4_TCELL_UP

DDR1 NBEA EPHA1

4.40e-04198203M3104
CoexpressionGSE43955_1H_VS_60H_ACT_CD4_TCELL_DN

DDR1 IL4R MCM3AP

4.47e-04199203M9651
CoexpressionGSE20715_0H_VS_24H_OZONE_TLR4_KO_LUNG_UP

DDR1 EPHA1 RERE

4.47e-04199203M4374
CoexpressionGSE360_L_MAJOR_VS_M_TUBERCULOSIS_DC_DN

GUCY2F SETD2 BRD2

4.47e-04199203M5214
CoexpressionGSE45739_UNSTIM_VS_ACD3_ACD28_STIM_WT_CD4_TCELL_UP

DDR1 EPHA1 RERE

4.53e-04200203M9886
CoexpressionGSE8921_3H_VS_24H_TLR1_2_STIM_MONOCYTE_UP

DDR1 ADAM22 PATJ

4.53e-04200203M6424
CoexpressionGSE23502_BM_VS_COLON_TUMOR_MYELOID_DERIVED_SUPPRESSOR_CELL_UP

ART3 EGR2 GAS7

4.53e-04200203M8087
CoexpressionGSE12392_IFNAR_KO_VS_IFNB_KO_CD8_NEG_SPLEEN_DC_DN

DDR1 IL4R PATJ

4.53e-04200203M7136
CoexpressionGSE17721_PAM3CSK4_VS_GADIQUIMOD_1H_BMDC_UP

EGR2 BRD2 PATJ

4.53e-04200203M3962
CoexpressionGSE39110_UNTREATED_VS_IL2_TREATED_CD8_TCELL_DAY6_POST_IMMUNIZATION_DN

ART3 EGR2 DDR1

4.53e-04200203M9285
CoexpressionGSE22886_NAIVE_BCELL_VS_BM_PLASMA_CELL_UP

SBNO1 DDR1 IL4R

4.53e-04200203M4442
CoexpressionGSE360_CTRL_VS_M_TUBERCULOSIS_DC_UP

GAS7 MCM3AP RERE

4.53e-04200203M5154
CoexpressionKAECH_NAIVE_VS_MEMORY_CD8_TCELL_UP

EGR2 RERE PATJ

4.53e-04200203M3020
CoexpressionGOLDRATH_EFF_VS_MEMORY_CD8_TCELL_DN

IL4R ADAM22 RERE

4.53e-04200203M3044
CoexpressionGSE360_LOW_DOSE_B_MALAYI_VS_M_TUBERCULOSIS_DC_UP

GAS7 MCM3AP RERE

4.53e-04200203M5229
CoexpressionBRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A

ART3 EGR2 DDR1 ADAM22 PATJ

4.74e-04899205M2242
CoexpressionBRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A

ART3 EGR2 DDR1 ADAM22 PATJ

5.53e-04930205MM893
CoexpressionLAKE_ADULT_KIDNEY_C3_PROXIMAL_TUBULE_EPITHELIAL_CELLS_S1_S2

ZC3H13 RERE PATJ

6.06e-04221203M39222
ToppCellPBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-4|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

CLEC17A IL4R RERE

5.97e-0517220362ed3b70fa1f6c84ea80ff00f60d2562be292e9d
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)

CLEC17A IL4R RERE

7.77e-05188203d8decd9b5967873ca8320c2f9f07365f163c777f
ToppCellrenal_medulla_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group

ESRRB RERE PATJ

7.89e-05189203830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCellBrain_organoid-organoid_Paulsen_bioRxiv-3_mon|organoid_Paulsen_bioRxiv / Sample Type, Dataset, Time_group, and Cell type.

SBNO1 ZC3H13 BRD2

8.53e-051942034903a0d6e36599bcb83b179462e5b949df9eb685
ToppCellPCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

GAS7 ADAM22 RERE

8.53e-05194203b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

ESRRB RERE PATJ

8.66e-051952036477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCellPCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung

GAS7 ADAM22 RERE

8.66e-051952030e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ESRRB RERE PATJ

8.79e-05196203eea66711a16134f86e6c533a5a837ff2e0d7ca7f
ToppCellmild-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

CLEC17A IL4R RERE

9.33e-05200203222789b897e2a683bbfd1d00b6fd8705015d90df
ToppCellmild-B_naive|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

CLEC17A IL4R RERE

9.33e-05200203d0467cab6a42bf780aa49046bf3231ca161dc144
ToppCellStriatum-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th-Inhibitory_Neuron.Gad1Gad2-Th.Trh_(Th+_interneuron)-|Striatum / BrainAtlas - Mouse McCarroll V32

ESRRB EPHA1

6.56e-048520286c5d71b66ff55c44d2d457865dda72e07e5ec53
ToppCellStriatum-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th-Inhibitory_Neuron.Gad1Gad2-Th.Trh_(Th+_interneuron)|Striatum / BrainAtlas - Mouse McCarroll V32

ESRRB EPHA1

6.56e-048520267336aa7ec02b64595ce7d5222d43cead92eb52e
ToppCellStriatum-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th|Striatum / BrainAtlas - Mouse McCarroll V32

ESRRB EPHA1

6.56e-0485202a7a5d82924cd4a41ab87b1abf13143635882a4b2
ToppCellPosterior_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

ART3 EPHA1

7.51e-04912027a60989eeb495e42e72e6d5d403e8d34027f9bd0
ToppCellPosterior_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Acta2Rgs5Rgs5_(Mural.Acta2Rgs5Rgs5)|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

ART3 EPHA1

7.51e-04912028f072b10386ef2742e7f95dcfbc42bfacf2af5f1
ToppCellPosterior_cortex-Endothelial-MURAL-M1(Rgs5Acta2)-M1_3-MURAL_Mural.Acta2Rgs5Rgs5_(Mural.Acta2Rgs5Rgs5)-|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

ART3 EPHA1

7.51e-0491202b576c4ab6ec2f80682dd51dc72dde35f99b1c7eb
ToppCellSubstantia_nigra-Endothelial-MURAL-M1(Rgs5Acta2)-M1_1-MURAL_Mural.Rgs5Acta2.Cbr2_(Mural.Rgs5Acta2.Cbr2)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

8.87e-04992020e2f6ba2261cc289f8f4aec5aac3051f6321e041
ToppCellSubstantia_nigra-Endothelial-MURAL-M1(Rgs5Acta2)-M1_1-MURAL_Mural.Rgs5Acta2.Cbr2_(Mural.Rgs5Acta2.Cbr2)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

8.87e-0499202ce9d6d9b82bdc1ebb58b0b6e04abfb022dd1de88
ToppCellSubstantia_nigra-Endothelial-MURAL-M1(Rgs5Acta2)-M1_1-MURAL_Mural.Rgs5Acta2.Fos_(Mural.Rgs5Acta2.Fos)-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

9.97e-0410520273639bfa677c7bb9e5166aa09eabaf1b05bb89a0
ToppCellSubstantia_nigra-Endothelial-MURAL-M1(Rgs5Acta2)-M1_1-MURAL_Mural.Rgs5Acta2.Fos_(Mural.Rgs5Acta2.Fos)|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

9.97e-0410520284b639eb44f71d1e12bb7850b9063d80e73cb741
ToppCellLPS-IL1RA-Epithelial_alveolar-AT_2-Airway|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ADAM22 EPHA1

1.39e-03124202d88bce8a4f023d5b617b2e8e372a94bd1248d20d
ToppCellSubstantia_nigra-Endothelial-MURAL-M1(Rgs5Acta2)-M1_1|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

1.45e-031272028c972ea21797ee46d6c67e91cfd2e2e2ce016248
ToppCellCerebellum-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Nrgn_(Inferior_colliculus)-|Cerebellum / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

1.48e-031282029a800beca5cfc7b41f5eed500d45064cfa61c5de
ToppCellCerebellum-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Nrgn_(Inferior_colliculus)|Cerebellum / BrainAtlas - Mouse McCarroll V32

EGR2 GLB1L2

1.48e-03128202920ede29f3de68e4d08644a1da53849e0c0973fb
ToppCellLV-03._Atrial_Cardiomyocyte|World / Chamber and Cluster_Paper

ART3 PATJ

1.52e-03130202a3e12984fb61311e49cc76c59f74f4dffc48faa1
ToppCellLPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DDR1 PATJ

1.59e-031332025bf5e654653e2c340891f51e3f2a30441b7b6b2b
ToppCellE16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Intermediate_Fibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass

RNF25 EPHA1

1.69e-03137202dd5364a1002650d21e0c83d8c701b5f7b09d1c19
ToppCellNS-moderate-d_16-33-Epithelial-unknown_epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

RERE BRD2

1.69e-0313720203e124901a0e85b59b6882bbafab568b50907e8b
ToppCell(08)_Brush+PNEC-(2)_GFP_FOXI1|(08)_Brush+PNEC / shred by cell type by condition

SBNO1 ZC3H13

1.71e-03138202817e3f639604ea95adae01e8685ffaa2e0aff7a8
ToppCelltumor_Lung-T/NK_cells-CD8_low_T|T/NK_cells / Location, Cell class and cell subclass

GAS7 EPHA1

1.81e-03142202eaf08a0dbacc9ebbd54e377922e76d8ba854dcb8
ToppCellMild/Remission-B_naive-1|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

IL4R PATJ

1.84e-03143202bd3f5fbd4e9e4dc414682db5607494f3ce988deb
ToppCellControl-Myeloid-Dendritic_cells|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

GAS7 ADAM22

1.84e-03143202bb8d4c335682d1a6798bed0de8bb0603054a4944
ToppCellsevere_COVID-19-B_cell|World / disease group, cell group and cell class (v2)

DDR1 ADAM22

1.84e-0314320228b0e168126a9fe60541dc12bfab385b7a0a2342
ToppCellsevere_COVID-19-B_cell|severe_COVID-19 / disease group, cell group and cell class (v2)

DDR1 ADAM22

1.86e-03144202c7f696e55e2d959c58ec32640c71ef86ee25203c
ToppCellFrontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Nptxr|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

SBNO1 EGR2

1.96e-03148202223d6a640f3c34e73646a615593b9c0b4a4cbd6f
ToppCellMild/Remission-B_naive-4|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)

IL4R RERE

1.96e-03148202dd5e1bc02824e743e1c030a303e32f27a359a8ca
ToppCellPND01-03-samps-Epithelial-Alveolar_epithelial-AT1_-_meso|PND01-03-samps / Age Group, Lineage, Cell class and subclass

DDR1 PATJ

2.02e-031502026a13e4c4b9c9e54a5016573a37132465ec1c8f99
ToppCell3'_v3-Lung-Lymphocytic_T_CD4-T_CD4/CD8|Lung / Manually curated celltypes from each tissue

ADAM22 PATJ

2.04e-03151202999c11d19b61d6b130ad5e623afa83cbdfe13cdd
ToppCelldroplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-myeloid_leukocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DDR1 ADAM22

2.07e-031522027e686721b95c837f2b0d5116927c8ecacef055ee
ToppCellLPS_only-Epithelial_alveolar-AT_1-AT2_Progenitor|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DDR1 PATJ

2.10e-03153202e7a074ea8232bacf924be78a244a8507c7e1ebc8
ToppCellInfluenza_Severe-Treg|Influenza_Severe / Disease group and Cell class

ADAM22 PATJ

2.12e-0315420277845bcb243aa1b1f1ca00f9ef2ae1b4d1bd3696
ToppCellPBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-5|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

CLEC17A IL4R

2.12e-03154202020697ae8463b18f9b4270c404f52ce4c0e90135
ToppCelldroplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DDR1 GLB1L2

2.12e-031542021e32969bee810adaf2d560f0824a16227df513d8
ToppCellSevere-B_naive-1|Severe / disease group and sub_cluster of B and Plasma cells(res = 0.5)

IL4R PATJ

2.26e-031592022881b054bbeb479221ee3c38bbd9b0815b123579
ToppCell3'-Distal_airway-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

DDR1 EPHA1

2.26e-031592021baf0eaf9684668146a63192e77eec6c3c7a37f8
ToppCellfacs-Brain_Myeloid-Cerebellum-3m-Myeloid-macrophage|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GAS7 DDR1

2.26e-03159202323cb4a2416d2e6bff0a3f225d2edeae9ab7dc76
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell-Schwann_Cell_/_Neural|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.29e-0316020214dfa519e68bab4bce890ddb66fa7763f18d9f19
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Neural|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.29e-031602025b7789d4668ed7732babedc32d812233b430e0bd
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell-Schwann_Cell_/_Neural-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.29e-03160202bba1486faaad5299e10f4fe17c6d149c28dc2560
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Neural-neural_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.29e-03160202839bbdfd4e4c7b48260c8bfb7670378634405e1d
ToppCellCOVID-CD8-CD8_2|COVID / Condition, Cell_class and T cell subcluster

EPHA1 PATJ

2.32e-03161202307dcc17475413cd9eb70c27bc447f938ee5723d
ToppCellChildren_(3_yrs)-Epithelial-lung_goblet_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

NBEA GLB1L2

2.32e-031612022d63b279d9a5132e1c09b03930bf9039036d24a2
ToppCellE18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

GAS7 IL4R

2.35e-03162202ec29c6f1c31e41ddcb041a49c593910edaf0532c
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Neural-neural_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.35e-03162202d28b2ea1d2c8f3c6a107991573471b6d0c49c4ae
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Neural-neural_cell-Schwann_Cell_/_Neural-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.35e-031622025bbd7130d4dad9035e73a439dda568195c136f31
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Neural-neural_cell-Schwann_Cell_/_Neural|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.35e-03162202eed223e61c8162a2fe004ab4e09de5e037be7553
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Neural|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ART3 GAS7

2.35e-03162202e35ddce830e20ebeac1a2c405293fc4a5323dd4a
ToppCell343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

RNF25 GLB1L2

2.37e-031632020ab043b68e8739adcedda01165a3758cd0d22728
ToppCellfacs-Lung-EPCAM-24m-Myeloid-lung_macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GAS7 ADAM22

2.40e-031642024e0133a7f80cf6bd3d70f72ee26360df5f80ab32
ToppCellfacs-Lung-EPCAM-24m-Myeloid-Interstitial_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GAS7 ADAM22

2.40e-031642024ab1a7d5379a633c3f61af1c8c2df93b6961d9cf
ToppCellE15.5-Endothelial-lymphatic_endothelial_cell-endothelial_cell_of_lymphatic_vessel|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

GAS7 IL4R

2.43e-031652028d3d5860a4785c4908160ae5fcb421ee80bd78ce
ToppCellE15.5-Endothelial-lymphatic_endothelial_cell|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

GAS7 IL4R

2.43e-0316520217ee6f269ed8d378465cf00ca59d48d8b106808e
ToppCellPBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-1|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

CLEC17A IL4R

2.43e-03165202fead3f2032f8fa5f7f0159a4434989b3d65debbb
ToppCellfacs-Lung-24m-Hematologic-myeloid-interstitial_macrophage-interstitial_macrophage_l12|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

GAS7 ADAM22

2.46e-031662027be2b5c62e2be3437ea50b9a473cf9fc7f05e0b1
ToppCellfacs-Lung-24m-Hematologic-myeloid-interstitial_macrophage|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

GAS7 ADAM22

2.46e-031662028418b191e7f16cb39301df3ddbfb1bab6c0632d6
ToppCellCOVID-19_Severe-CD4+_T_activated|COVID-19_Severe / Disease condition and Cell class

EPHA1 PATJ

2.46e-031662020f138dbafad6f83975944e8f6398411127b150cc
ToppCellsevere-CD4+_T_naive|severe / disease stage, cell group and cell class

CLEC17A PATJ

2.49e-0316720202a8215fca59c357c1cdaa5738849eacf98c0bcc
ToppCelldroplet-Lung-LUNG-30m-Myeloid-dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DDR1 ADAM22

2.52e-031682020e8b0e6399c6c82c9c0e546f7316f902de0765d3
ToppCellP28-Epithelial-airway_epithelial_cell-ciliated_cell_of_airway|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

DDR1 PATJ

2.52e-031682028c8dbdbc7053f34e4ca0c5067af502fbea109fc1
ToppCellCOVID-19-Heart-Neuronal|COVID-19 / Disease (COVID-19 only), tissue and cell type

ART3 GAS7

2.52e-0316820288c2c574f428c2502b5fe099bd73b0758f668ef6
ToppCell390C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-2|390C / Donor, Lineage, Cell class and subclass (all cells)

EPHA1 PATJ

2.55e-03169202cfc9ff103d13a2d5eacc457e800f53fdd29f7738
ToppCellMild/Remission-B_naive-4|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)

IL4R RERE

2.55e-03169202c3a6179a64589a370108fea809b157839347759c
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

CLEC17A GAS7

2.55e-03169202b2fdf9f842dc7c181bc951a8a6932c916ed835ef
ToppCellControl-Mast_cells|Control / group, cell type (main and fine annotations)

GAS7 NBEA

2.55e-03169202fdb9abca1d0f4fdc32dd8ac6231651ef34aa5afb
ToppCellPND10-Immune-Immune_Myeloid-DC-maDC-maDC_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IL4R ADAM22

2.55e-03169202a83e4078db91ecedee637b28b12ec38640fe45f9
ToppCellPND10-Immune-Immune_Myeloid-DC-maDC|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

IL4R ADAM22

2.55e-03169202f914aa8899fa170a09da31e5fad86de897ea789b
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Immune-Myeloid-Monocytic-Monocyte-derived_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

CLEC17A GAS7

2.55e-031692022322f03a115c662f808ebfc892192b7d38d48181
ToppCellCOVID-19_Mild-PLT_2|World / Disease Group and Platelet Clusters

RNF25 MCM3AP

2.55e-031692026abfdc8b437f19c03b408bedc245059d28c6ba6a
ToppCellControl-Mast_cells-Mast_cells|Control / group, cell type (main and fine annotations)

GAS7 NBEA

2.58e-03170202c80f6d29096c372da95a8407f402349ff1bb7018
ToppCellP07-Epithelial-epithelial_progenitor_cell-epithelial_unknown_3|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

ART3 GAS7

2.64e-031722028d6a2a0d5f63b09a5a304a77e600a647f87e9de4
ToppCellImmune_cells-B_cell|Immune_cells / Lineage and Cell class

EGR2 IL4R

2.64e-03172202b646894b691a99bf2742bd9da8e578dff0e87f1f
ToppCelldroplet-Spleen-SPLEEN-30m-Myeloid-macrophage_dendritic_cell_progenitor|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GAS7 DDR1

2.64e-0317220230916a902c151907745756d14327e24adc34afef
ToppCellfacs-Heart-LV-18m-Mesenchymal-valve_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ART3 DDR1

2.67e-03173202d78397e65e997ddb995111a810f0e2a4f67d0765
ToppCellCOVID-19_Mild-PLT_2|COVID-19_Mild / Disease Group and Platelet Clusters

RNF25 MCM3AP

2.67e-03173202d11705e56b6b21eec963ea224717f27680c781ed
ToppCellfacs-Heart-LV-18m-Mesenchymal-valve_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ART3 DDR1

2.67e-031732023c852ffe22f4a5b632463086b08c669310684e80
ToppCellwk_20-22-Epithelial-PNS|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

ART3 GAS7

2.67e-0317320217b1a6b0318925d5d920f2c0a791745b9587ebef
ToppCell5'-GW_trimst-2-LymphNode-Neuronal-Glial_immature-Glia_1_(DHH+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ART3 GAS7

2.70e-031742021463c98f8f519dd030587abbdbeb1b4e1bca5dd1
ToppCell5'-GW_trimst-2-LymphNode-Neuronal-Glial_immature|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ART3 GAS7

2.70e-03174202c9d4e375dedd2b099a9ed70ec38ff35bbb0ce48a
ToppCell5'-GW_trimst-2-LymphNode-Neuronal|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ART3 GAS7

2.70e-03174202d421c0069d24cb560a3a429929e3cd1eceaeabcf
ToppCell3'-GW_trimst-1.5-SmallIntestine-Neuronal-Glial_immature-Glia_1_(DHH+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ART3 GAS7

2.70e-03174202667035a11b68745fa8446d6c68214713be42710f
ToppCellPrimary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L5-6_FEZF2_ANKRD20A1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

ART3 IL4R

2.70e-0317420299eb5e1aee136c7039e23b68a43a0fa3d775859f
ToppCellPND10-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

DDR1 PATJ

2.73e-03175202442f261a3b2c4d2523f7d4089178f8c79cac2f0f
ToppCelldroplet-Kidney-KIDNEY-30m-Mesenchymal-podocyte|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

EPHA1 PATJ

2.73e-0317520231f0fb2e47e357dbf9c15436b7df85b3c370ded7
ToppCellfacs|World / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

GAS7 EPHA1

2.73e-0317520253e96956019f984decc1c81376ebc88fbf3c4d40
ToppCellPND10-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1/AT2-AT1/AT2_mature|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

DDR1 PATJ

2.73e-0317520235fb7735dd3355476fe60404833cb60bd066bcf1
ToppCell5'-Adult-Appendix-Hematopoietic-B_cells-Naive_B|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CLEC17A IL4R

2.73e-03175202d544f24ee33783ed4afb4d7ec079a4484118bb15
ToppCellFrontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

SBNO1 EGR2

2.73e-0317520221f8f11a8b874d4f7c47931010a2535f2a5a3373
ToppCellFrontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

SBNO1 EGR2

2.73e-03175202ff0789f5913c9f3c49159e40b1ec3d2ff175ec9f
ToppCellPBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-1|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

CLEC17A IL4R

2.76e-03176202ad05dd934f4ac2e656b3455de091f4c8772de6c8
ToppCell343B-Lymphocytic-NK_cells-NK_cell_D3|NK_cells / Donor, Lineage, Cell class and subclass (all cells)

NBEA EPHA1

2.76e-03176202bd5c85b3a4fb88ffe156599f6d224aa7664a513a
DrugMethiazole; Down 200; 15uM; PC3; HT_HG-U133A

IL4R MCM3AP EPHA1 RERE PATJ

6.43e-071972054532_DN
DrugDiprophylline [479-18-5]; Up 200; 15.8uM; MCF7; HT_HG-U133A

GAS7 IL4R ZC3H13 RERE PATJ

6.43e-071972055482_UP
DrugConvolamine hydrochloride [500-56-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A

IL4R ADAM22 ZC3H13 EPHA1 RERE

6.59e-071982052771_DN
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; PC3; HT_HG-U133A

IL4R MCM3AP EPHA1 PATJ

2.18e-051932043814_DN
DrugMetampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

GAS7 ADAM22 SETD2 EPHA1

2.27e-051952045115_UP
DrugDipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A

GAS7 ADAM22 SETD2 MCM3AP

2.27e-051952043835_DN
DrugCefaclor [70356-03-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A

IL4R ADAM22 RERE PATJ

2.32e-051962042843_DN
DrugMeclofenamic acid sodium salt monohydrate [6385-02-0]; Down 200; 11.8uM; HL60; HG-U133A

SBNO1 GAS7 SETD2 MCM3AP

2.32e-051962041445_DN
DrugMeclozine dihydrochloride [1104-22-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A

IL4R ADAM22 ZC3H13 EPHA1

2.36e-051972045244_DN
DrugDenatonium benzoate [3734-33-6]; Up 200; 9uM; MCF7; HT_HG-U133A

GAS7 IL4R ADAM22 ZC3H13

2.36e-051972045480_UP
DrugVincamine [1617-90-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A

RNF25 ADAM22 MCM3AP RERE

2.36e-051972043865_DN
DrugPicotamide monohydrate [80530-63-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A

IL4R EPHA1 RERE GLB1L2

2.36e-051972046787_DN
Drug(-)-MK 801 hydrogen maleate [77086-19-2]; Up 200; 11.8uM; MCF7; HT_HG-U133A

GAS7 ADAM22 RERE PATJ

2.41e-051982046458_UP
DrugLY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A

IL4R ADAM22 EPHA1 PATJ

2.41e-051982046976_UP
Drug(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; HL60; HT_HG-U133A

GAS7 GUCY2F EPHA1 RERE

2.41e-051982042197_UP
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A

GAS7 IL4R EPHA1 RERE

2.41e-051982043897_DN
Drug0173570-0000 [211245-44-2]; Up 200; 1uM; PC3; HT_HG-U133A

GAS7 MCM3AP RERE PATJ

2.41e-051982047391_UP
DrugGlycocholic acid [475-31-0]; Up 200; 8.6uM; MCF7; HT_HG-U133A

RNF25 SETD2 EPHA1 PATJ

2.41e-051982045316_UP
Drugcatechin; Down 200; 11uM; MCF7; HT_HG-U133A_EA

NBEA SETD2 RERE GLB1L2

2.41e-051982041101_DN
DrugDanazol [17230-88-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A

IL4R ADAM22 SETD2 PATJ

2.41e-051982041538_UP
DrugLisinopril [83915-83-7]; Up 200; 9uM; MCF7; HT_HG-U133A

GAS7 ZC3H13 EPHA1 RERE

2.46e-051992045504_UP
DrugLetrozole [112809-51-5]; Up 200; 14uM; MCF7; HT_HG-U133A

GAS7 ADAM22 ZC3H13 EPHA1

2.46e-051992047336_UP
DrugDenatonium benzoate [3734-33-6]; Up 200; 9uM; MCF7; HT_HG-U133A

GAS7 ADAM22 MCM3AP RERE

2.51e-052002046502_UP
DrugSperact

GUCY2F BRD2

2.00e-0424202CID000123688
DrugDL-arginine

ART3 GUCY2F SETD2 RERE

2.05e-04344204CID000000232
Drugindigo carmine

RNF25 GUCY2F

2.17e-0425202CID005282429
Drugcopper complex

RNF25 EGR2

2.35e-0426202CID000410253
DrugI vs

DDR1 SETD2 RERE

2.77e-04147203CID000444340
Drugiodomelatonin

ART3 RERE

3.14e-0430202CID000115348
DrugAC1L1K7W

IL4R ESRRB

4.04e-0434202CID000005377
DrugMetaproterenol sulfate, orciprenaline sulfate [5874-97-5]; Up 200; 7.6uM; PC3; HT_HG-U133A

ZC3H13 MCM3AP PATJ

4.94e-041792034248_UP
DrugRolitetracycline [751-97-3]; Down 200; 7.6uM; MCF7; HT_HG-U133A

ADAM22 RERE PATJ

5.43e-041852033369_DN
Drugfluphenazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A

IL4R EPHA1 PATJ

5.52e-041862036996_UP
DrugICI 182,780; Down 200; 0.01uM; MCF7; HT_HG-U133A

IL4R MCM3AP RERE

5.61e-041872035598_DN
DrugTerfenadine [50679-08-8]; Down 200; 8.4uM; HL60; HG-U133A

SBNO1 SETD2 RERE

5.78e-041892031381_DN
DrugEconazole nitrate [24169-02-6]; Up 200; 9uM; PC3; HT_HG-U133A

IL4R RERE PATJ

5.87e-041902037305_UP
DrugYC-1 compound

GUCY2F SETD2

5.89e-0441202CID000005712
DrugTerfenadine [50679-08-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A

ADAM22 MCM3AP EPHA1

5.96e-041912032227_DN
DrugBetamethasone [378-44-9]; Up 200; 10.2uM; PC3; HT_HG-U133A

ADAM22 ZC3H13 MCM3AP

6.05e-041922036728_UP
DrugMetampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; PC3; HT_HG-U133A

IL4R SETD2 EPHA1

6.05e-041922032123_UP
DrugEtofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A

GAS7 ADAM22 PATJ

6.05e-041922034108_UP
DrugEpitiostanol [2363-58-8]; Up 200; 13uM; MCF7; HT_HG-U133A

GAS7 ADAM22 EPHA1

6.15e-041932034788_UP
DrugTolazamide [1156-19-0]; Up 200; 12.8uM; MCF7; HT_HG-U133A

GAS7 ADAM22 SETD2

6.15e-041932032842_UP
DrugCaptopril [62571-86-2]; Up 200; 17.2uM; HL60; HG-U133A

SBNO1 SETD2 MCM3AP

6.15e-041932031988_UP
DrugMethylhydantoin-5-(L) [40856-73-3]; Down 200; 35uM; MCF7; HT_HG-U133A

ADAM22 RERE PATJ

6.15e-041932033378_DN
DrugFenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A

IL4R SETD2 RERE

6.15e-041932033412_DN
DrugChlorpheniramine maleate [113-92-8]; Up 200; 10.2uM; PC3; HT_HG-U133A

ADAM22 SETD2 RERE

6.15e-041932032055_UP
DrugCefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A

ART3 GAS7 PATJ

6.15e-041932037385_UP
DrugKarakoline [39089-30-0]; Down 200; 10.6uM; MCF7; HT_HG-U133A

ADAM22 ZC3H13 EPHA1

6.24e-041942034763_DN
DrugDosulepin hydrochloride [897-15-4]; Down 200; 12uM; MCF7; HT_HG-U133A

SETD2 RERE PATJ

6.24e-041942032864_DN
DrugPF-00875133-00 [351322-64-0]; Up 200; 10uM; MCF7; HT_HG-U133A

GAS7 IL4R ADAM22

6.24e-041942035923_UP
DrugAcyclovir [59277-89-3]; Down 200; 17.8uM; MCF7; HT_HG-U133A

ZC3H13 RERE PATJ

6.24e-041942035278_DN
DrugVerapamyl hydrochloride [152-11-4]; Down 200; 8.2uM; HL60; HG-U133A

SBNO1 GAS7 SETD2

6.24e-041942032009_DN
DrugPindolol [13523-86-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A

ADAM22 RERE PATJ

6.24e-041942032238_DN
DrugSertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A

GAS7 IL4R EPHA1

6.24e-041942036811_DN
DrugEtifenin [63245-28-3]; Up 200; 12.4uM; MCF7; HT_HG-U133A

GAS7 ADAM22 EPHA1

6.24e-041942034117_UP
Drug2-propylpentanoic acid; Down 200; 50uM; HL60; HT_HG-U133A

GAS7 IL4R RERE

6.33e-041952031163_DN
DrugAcenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A

ADAM22 EPHA1 PATJ

6.33e-041952035878_UP
DrugFluspirilen [1841-19-6]; Up 200; 8.4uM; PC3; HT_HG-U133A

ADAM22 ZC3H13 GLB1L2

6.33e-041952036662_UP
DrugButoconazole nitrate [32872-77-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A

IL4R SETD2 EPHA1

6.33e-041952035388_DN
DrugFlurandrenolide [1524-88-5]; Up 200; 9.2uM; MCF7; HT_HG-U133A

GAS7 ADAM22 MCM3AP

6.33e-041952036039_UP
DrugAlfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A

GAS7 MCM3AP EPHA1

6.33e-041952035451_UP
DrugEthynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A

ZC3H13 EPHA1 RERE

6.33e-041952034792_UP
DrugSulfamerazine [127-79-7]; Down 200; 15.2uM; MCF7; HT_HG-U133A

GAS7 MCM3AP RERE

6.33e-041952034740_DN
DrugMethoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; PC3; HT_HG-U133A

IL4R EPHA1 RERE

6.33e-041952036661_DN
DrugMyricetin [529-44-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

GAS7 ADAM22 RERE

6.33e-041952034170_DN
DrugProglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A

GAS7 ADAM22 RERE

6.33e-041952033972_DN
DrugQuinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

MCM3AP EPHA1 PATJ

6.33e-041952033191_DN
DrugSC 19220; Up 200; 10uM; MCF7; HT_HG-U133A

GAS7 IL4R ADAM22

6.33e-041952037060_UP
Drug17-AAG; Up 200; 1uM; ssMCF7; HG-U133A

SBNO1 ADAM22 ZC3H13

6.33e-04195203521_UP
DrugPromazine hydrochloride [53-60-1]; Down 200; 12.4uM; MCF7; HT_HG-U133A

EPHA1 RERE PATJ

6.43e-041962036028_DN
Drug(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; PC3; HT_HG-U133A

ADAM22 RERE PATJ

6.43e-041962033789_DN
DrugFlutamide [13311-84-7]; Down 200; 14.4uM; PC3; HT_HG-U133A

IL4R SETD2 PATJ

6.43e-041962034539_DN
DrugDeferoxamine mesylate [138-14-7]; Down 200; 6uM; MCF7; HT_HG-U133A

RNF25 ADAM22 MCM3AP

6.43e-041962033842_DN
DrugDemecarium bromide [56-94-0]; Up 200; 5.6uM; MCF7; HT_HG-U133A

ADAM22 RERE PATJ

6.43e-041962036269_UP
DrugIopamidol [60166-93-0]; Up 200; 5.2uM; MCF7; HT_HG-U133A

SBNO1 GAS7 ADAM22

6.43e-041962033473_UP
Drugvalinomycin; Down 200; 0.1uM; PC3; HT_HG-U133A

GAS7 ADAM22 MCM3AP

6.43e-041962035962_DN
DrugHexamethonium dibromide dihydrate [55-97-0]; Up 200; 10uM; MCF7; HT_HG-U133A

ADAM22 ZC3H13 RERE

6.43e-041962034965_UP
DrugNomegestrol acetate [58652-20-3]; Up 200; 10.8uM; MCF7; HT_HG-U133A

ADAM22 MCM3AP EPHA1

6.43e-041962035461_UP
DrugFenofibrate [49562-28-9]; Up 200; 11uM; MCF7; HT_HG-U133A

IL4R ADAM22 EPHA1

6.43e-041962037432_UP
DrugLabetalol hydrochloride [32780-64-6]; Down 200; 11uM; MCF7; HT_HG-U133A

RNF25 MCM3AP EPHA1

6.43e-041962033167_DN
DrugHeliotrine [303-33-3]; Down 200; 12.8uM; MCF7; HT_HG-U133A

GAS7 SETD2 EPHA1

6.43e-041962034739_DN
DrugPractolol [6673-35-4]; Up 200; 15uM; MCF7; HT_HG-U133A

GAS7 ADAM22 PATJ

6.43e-041962033204_UP
DrugGuanadrel sulfate [22195-34-2]; Up 200; 7.6uM; MCF7; HT_HG-U133A

ADAM22 ZC3H13 MCM3AP

6.43e-041962034720_UP
DrugMetrizamide [31112-62-6]; Down 200; 5uM; MCF7; HT_HG-U133A

ADAM22 SETD2 EPHA1

6.43e-041962033255_DN
DrugProguanil hydrochloride [637-32-1]; Down 200; 13.8uM; HL60; HT_HG-U133A

GAS7 NBEA RERE

6.43e-041962032944_DN
DrugNalidixic acid sodium salt hydrate; Up 200; 14.6uM; PC3; HT_HG-U133A

GAS7 ADAM22 ZC3H13

6.43e-041962033668_UP
DrugTenoxicam [59804-37-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A

GAS7 ADAM22 ZC3H13

6.43e-041962034182_DN
DrugNialamide [51-12-7]; Up 200; 13.4uM; MCF7; HT_HG-U133A

GAS7 ADAM22 ZC3H13

6.43e-041962034347_UP
DrugHemicholinium bromide [312-45-8]; Up 200; 7uM; MCF7; HT_HG-U133A

GAS7 ADAM22 PATJ

6.43e-041962035339_UP
DrugCinchonine [118-10-5]; Up 200; 13.6uM; HL60; HT_HG-U133A

RNF25 NBEA EPHA1

6.43e-041962032133_UP
DrugMethyldopa (L,-) [555-30-6]; Up 200; 19uM; MCF7; HT_HG-U133A

GAS7 EPHA1 RERE

6.52e-041972035637_UP
DrugTamoxifen citrate [54965-24-1]; Down 200; 7uM; MCF7; HT_HG-U133A

ADAM22 SETD2 PATJ

6.52e-041972036768_DN
DrugMephentermine hemisulfate [1212-72-2]; Up 200; 9.4uM; PC3; HT_HG-U133A

ADAM22 ZC3H13 PATJ

6.52e-041972033685_UP
DrugDehydrocholic acid [81-23-2]; Up 200; 9.6uM; PC3; HT_HG-U133A

GAS7 ADAM22 PATJ

6.52e-041972034620_UP
DrugBenfotiamine [22457-89-2]; Down 200; 8.6uM; MCF7; HT_HG-U133A

GAS7 ADAM22 PATJ

6.52e-041972033837_DN
DrugSertaconazole nitrate [99592-39-9]; Down 200; 8uM; MCF7; HT_HG-U133A

ADAM22 EPHA1 GLB1L2

6.52e-041972033550_DN
DrugTrichlormethiazide [133-67-5]; Up 200; 10.6uM; PC3; HT_HG-U133A

GAS7 ADAM22 PATJ

6.52e-041972034198_UP
DrugChlorpheniramine maleate [113-92-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A

ADAM22 EPHA1 GLB1L2

6.52e-041972036773_DN
DrugCarbimazole [22232-54-8]; Up 200; 21.4uM; MCF7; HT_HG-U133A

ADAM22 ZC3H13 RERE

6.52e-041972033299_UP
Diseaseadult onset asthma

IL4R RERE BRD2

5.77e-05118193EFO_1002011
DiseaseSquamous cell carcinoma of lung

GUCY2F DDR1

1.93e-0432192C0149782
Diseaselymphocyte count

SBNO1 EGR2 SETD2 MCM3AP RERE BRD2

2.29e-041464196EFO_0004587
DiseaseCharcot-Marie-Tooth disease

EGR2 MCM3AP

3.33e-0442192cv:C0007959
Diseaseallergic disease

SBNO1 IL4R RERE

5.77e-04258193MONDO_0005271
Diseasemonocyte percentage of leukocytes

EGR2 SETD2 MCM3AP RERE

1.08e-03731194EFO_0007989
Diseaseautism spectrum disorder, schizophrenia

DDR1 RERE BRD2

1.15e-03327193EFO_0003756, MONDO_0005090
Diseaseeosinophil percentage of leukocytes

EGR2 IL4R SETD2 RERE

1.16e-03746194EFO_0007991
Diseaseschizophrenia, intelligence, self reported educational attainment

EGR2 GAS7 RERE

1.35e-03346193EFO_0004337, EFO_0004784, MONDO_0005090
DiseaseInhalant adrenergic use measurement

IL4R RERE

1.73e-0396192EFO_0009941
DiseaseHIV-1 infection

DDR1 NBEA

1.80e-0398192EFO_0000180
Diseaseattention deficit hyperactivity disorder, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia

CLEC17A RERE

1.91e-03101192EFO_0003756, EFO_0003761, EFO_0003888, MONDO_0004985, MONDO_0005090
DiseaseGlioblastoma Multiforme

GUCY2F BRD2

2.30e-03111192C1621958
DiseasePapillary Renal Cell Carcinoma

IL4R SETD2

3.04e-03128192C1306837
DiseaseRenal Cell Carcinoma

IL4R SETD2

3.04e-03128192C0007134
DiseaseSarcomatoid Renal Cell Carcinoma

IL4R SETD2

3.04e-03128192C1266043
DiseaseChromophobe Renal Cell Carcinoma

IL4R SETD2

3.04e-03128192C1266042
DiseaseCollecting Duct Carcinoma of the Kidney

IL4R SETD2

3.04e-03128192C1266044
Diseasestomach cancer (is_marker_for)

NBEA SETD2

3.73e-03142192DOID:10534 (is_marker_for)
Diseaserespiratory system disease

IL4R RERE

3.88e-03145192EFO_0000684
DiseaseConventional (Clear Cell) Renal Cell Carcinoma

IL4R SETD2

4.04e-03148192C0279702
Diseaseautism spectrum disorder

EGR2 ESRRB

4.48e-03156192EFO_0003756
Diseasecolorectal cancer (is_marker_for)

DDR1 SETD2

4.53e-03157192DOID:9256 (is_marker_for)

Protein segments in the cluster

PeptideGeneStartEntry
PPPVDCPAPLYELMK

EPHA1

846

P21709
DYMEPEKPGAPLLPP

DDR1

546

Q08345
PYPMPPLPDEDKKVN

ADAM22

881

Q9P0K1
PKPATDPGLFPMIPD

EGR2

211

P11161
PPPPEPVPMYSDEDL

MCM3AP

1066

O60318
EPGEKVEDMPKPPLP

IL4R

681

P24394
FMKPLPVPPPVDKDG

GUCY2F

1066

P51841
PPDLLPKMPYEPLTP

GLB1L2

376

Q8IW92
PDKLYAMPPPGMPEG

ESRRB

221

O95718
LDSPMVSPPPDYPGE

SBNO1

1056

A3KN83
YVQLLEKPGMVPPPP

GAS7

56

O60861
GPEPIPYPDPALKRE

NBEA

1761

Q8NFP9
ELPPIEKPVDPPPFM

RERE

541

Q9P2R6
AKMPDEPLEPGPLPV

BRD2

451

P25440
PPYKDLPPKPGTMEE

CLEC17A

31

Q6ZS10
PPPMKLPPPYKALTD

PATJ

1196

Q8NI35
ELPPPEGPLKEPMDL

RNF25

371

Q96BH1
PQPPPKMGDFYDPEH

SETD2

6

Q9BYW2
PPPPIPEDIALGKKY

ZC3H13

266

Q5T200
QIPGMKIPEPFPLPE

ART3

321

Q13508